|
10:00am-11:15am SESSION 5: Introduction to Day 2 and second plenary
|
| |
|
10:00am - 10:15am
|
Introduction to Day 2
Darren Jones, Head of Product Development, Cellmid Ltd
|
|
10:15am - 11:15am
|
PLENARY 2
Midkine: An enigmatic but interesting growth factor
Dr Kenji Kadomatsu, Nagoya University Graduate School of Medicine, Nagoya, Japan
|
|
11:15am - 11:15am
|
Morning tea and poster session
|
| |
|
11:45am - 12:15pm SESSION 6: The Zebrafish- a powerful model to understand MK biology
|
| |
|
11:45am - 12:15pm
|
Midkine function in the developing nervous system of zebrafish
Dr Christoph Winkler, Dept of Biological Sciences, National University of Singapore, Singapore
|
|
12:15pm - 12:45pm
|
Expression and function of midkines in the zebrafish retina
Dr Peter Hitchcock, Dept of Ophthalmology and Visual Sciences, University of Michigan, USA
|
|
12:45pm -1:45pm
|
Lunch
|
| |
|
1:45pm -3:15pm SESSION 7: Targeting MK- new treatment opportunities
|
| |
|
1:45pm - 2:15pm
|
New roles of MK in modulating morphine-induced analgesia
Dr Gonzalo Herradon, University San Pablo CEU, Spain
|
|
2:15pm - 2:45pm
|
Glioblastoma MK correlates with treatment failure of Glivec in combination with Roscovitine and indomethicine
Dr Mine Erguven,Yeni Yuzyil University, Istanbul, Turkey
|
|
2:45pm - 3:15pm
|
Suppression of hepatocellular carcinoma growth by MK antisense oligonucleotide nanoliposomes
Dr Dai Licheng, Huzhou Central Hospital, Huzhou, China
|
|
3:15pm - 3:45pm
|
Afternoon tea and poster viewing
|
| |
|
3:45pm - 4:45pm SESSION 8: Midkine in Brain and Heart Infarction
|
| |
|
3:45pm - 4:15pm
|
Protective effects of MK gene transfer in brain infarction
Dr Hiroaki Ooboshi, Fukuoka Medical & Dental Hospital, Fukuoka, Japan
|
|
4:15pm - 4:45pm
|
A preclinical program for MK protein to treat AMI
Dr Peter Ferdinandy, CEO, Pharmahungary, Szeged, Hungary
|
|
4:45pm - 5:00pm
|
Closing remarks and general discussion
|
|
7:00pm - 11:00pm Conference dinner, Nick’s Bar & Grill, King St Wharf
|